Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27892014 | 0.83 | ALDH1A1 (0.41) | ALDH1A1KDM4ESMN1; SMN2MAPTRAB9A | |
| SCHEMBL936466 | 0.82 | ALDH1A1 (0.45) | ALDH1A1KDM4ESMN1; SMN2MAPTRAB9A | |
| SCHEMBL937188 | 0.79 | KMT2A (0.49) | ALDH1A1KDM4ESMN1; SMN2RAB9AKMT2A | |
| SCHEMBL936475 | 0.79 | KMT2A (0.49) | ALDH1A1KDM4ESMN1; SMN2RAB9AKMT2A | |
| SCHEMBL936476 | 0.79 | KMT2A (0.49) | ALDH1A1KDM4ESMN1; SMN2RAB9AKMT2A | |
| SCHEMBL936471 | 0.78 | PIM1 (0.57) | HPGD | |
| SCHEMBL936472 | 0.78 | PIM1 (0.57) | HPGD | |
| SCHEMBL936767 | 0.77 | KMT2A (0.48) | ALDH1A1SMN1; SMN2MAPTKMT2AMEN1 | |
| SCHEMBL936657 | 0.75 | MAOA (0.43) | ALDH1A1RAB9AKMT2ACYP3A4LMNA | |
| SCHEMBL10694902 | 0.74 | ALDH1A1 (0.62) | ALDH1A1KDM4ESMN1; SMN2MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3202401-B1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CIRIUS THERAPEUTICS INC (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-2513070-B1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | CIRIUS THERAPEUTICS INC (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3202401-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Octeta Therapeutics, LLC (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-2512470-B1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | OCTETA THERAPEUTICS LLC (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2016-02-25 | — | — | US | disclosed |
| EP-2931274-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Metabolic Solutions Development Company LLC (US) | 2015-10-21 | — | — | EP | disclosed |
| US-9126959-B2 | PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150051406-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2015-02-19 | — | — | US | disclosed |
| US-8912335-B2 | PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| WO-2014093114-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY LLC (US) | 2014-06-19 | — | — | WO | disclosed |
| WO-2011133611-A1 | THIAZOLIDINEDIONE ANALOGUES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011084453-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011084459-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF OBESITY AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011084456-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF DIABETES MELLITUS AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011075514-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2010105048-A9 | THIAZOLIDINEDIONE ANALOGUES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010105048-A1 | THIAZOLIDINEDIONE ANALOGUES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2010-09-16 | — | — | WO | disclosed |
| US-20100222399-A1 | Thiazolidinedione Analogues For The Treatment Of Hypertension | CIRIUS THERAPEUTICS, INC. | 2010-09-02 | — | — | US | disclosed |
| EP-2203433-A1 | THIAZOLIDINEDIONE ANALOGUES FOR THE TREATMENT OF HYPERTENSION | Metabolic Solutions Development Company (US) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009038681-A1 | THIAZOLIDINEDIONE ANALOGUES FOR THE TREATMENT OF HYPERTENSION | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222399-A1 | Thiazolidinedione Analogues For The Treatment Of Hypertension | AGTR2, ADRB1, ADRB3 | ALDH1A1 500/4885KDM4E 2910/4885SMN1; SMN2 4871/4885 |
| US-20150051406-A1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | PPARD, PPARG, PPARA | ALDH1A1 783/4885KDM4E 3252/4885SMN1; SMN2 1843/4885 |
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | PPARD, PPARG, PPARA | ALDH1A1 1510/4885KDM4E 2439/4885SMN1; SMN2 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.